{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:04:24Z","timestamp":1767942264071,"version":"3.49.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jns.2025.125688","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:29:35Z","timestamp":1764808175000},"page":"125688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Steroid-sparing in myasthenia gravis: How much is efgartigimod, and How much is carryover?"],"prefix":"10.1016","volume":"480","author":[{"given":"Christian","family":"Messina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.125688_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123652","article-title":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","volume":"477","author":"Goyal","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2025.125688_bb0010","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2025.125688_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00415-025-13113-0","article-title":"Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis","volume":"272","author":"Hewamadduma","year":"2025","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.125688_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of Ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 champion MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125688_bb0025","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s10072-023-07082-3","article-title":"Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: long-term outcomes","volume":"45","author":"Kefalopoulou","year":"2024","journal-title":"Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2025.125688_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201501","article-title":"Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in Myasthenia Gravis","volume":"100","author":"Bril","year":"2023","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:20:22Z","timestamp":1767936022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25023081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":6,"alternative-id":["S0022510X25023081"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125688","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steroid-sparing in myasthenia gravis: How much is efgartigimod, and How much is carryover?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125688"}}